Scientific Sessions 2024  /  Featured Science: Novel Approaches to Managing Lipid Risk  /  Novel Lipid Targets and Vascular Outcomes
Logo

American Heart Association

  113
  0

Final ID:

Novel Lipid Targets and Vascular Outcomes

  • Libby, Peter  ( BRIGHAM AND WOMENS HOSPITAL , Boston , Massachusetts , United States )
  • Ginsberg, Henry  ( COLUMBIA UNIVERSITY , New York , New York , United States )
    • Author Disclosures:
    Peter Libby: DO have relevant financial relationships ; Consultant:Amgen, Baim Institute, Beren Therapeutics, Esperion Therapeutics, Genentech, Kancera, Kowa Pharmaceuticals, Novo Nordisk, Novartis, and Sanofi-Regeneron:Active (exists now) ; Other (please indicate in the box next to the company name):Dr. Libby is on the Board of Directors of XBiotech, Inc. Dr. Libby has a financial interest in Xbiotech, a company developing therapeutic human antibodies, in TenSixteen Bio, a company targeting somatic mosaicism and clonal hematopoiesis of indeterminate potential (CHIP) to discover and develop novel therapeutics to treat age-related diseases, and in Soley Therapeutics, a biotechnology company that is combining artificial intelligence with molecular and cellular response detection for discovering and developing new drugs, currently focusing on cancer therapeutics. Dr. Libby’s interests were reviewed and are managed by Brigham and Women’s Hospital and Mass General Brigham in accordance with their conflict-of-interest policies.:Active (exists now) ; Other (please indicate in the box next to the company name):Dr. Libby’s laboratory has received research funding in the last 2 years from Novartis, Novo Nordisk and Genentech:Active (exists now) ; Advisor:AmAmgen, Caristo Diagnostics, CSL Behring, Elucid Bioimaging, Kancera, Kowa Pharmaceuticals, Olatec Therapeutics, Novartis, PlaqueTec, Polygon Therapeutics, TenSixteen Bio, Soley Thereapeutics, and XBiotech, Inc.:Active (exists now) | Henry Ginsberg: DO NOT have relevant financial relationships
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Featured Science: Novel Approaches to Managing Lipid Risk

Saturday, 11/16/2024 , 01:30PM - 02:45PM

Featured Science

More abstracts on this topic:
Efficacy and Safety of Lerodalcibep, a Third Generation PCSK9 Inhibitor, in 703 Heterozygous Familial Hypercholesterolemia Subjects in the Open Label Extension Trial

Raal Frederick, Fourie Nyda, Scott Russell, Blom Dirk, Kayikcioglu Meral, Vest Jeff, Kallend David, Stein Evan

Long-term Efficacy of Lerodalcibep in 1,468 Patients at Very High and High Risk for CVD in the 72 week Open-Label Extension Trial

Kereiakes Dean, Fourie Nyda, Scott Russell, Asprusten Emil, Yalim Zafer, Vest Jeff, Kallend David, Stein Evan

More abstracts from these authors:
History and Significance of the Duff Lectureship

Ginsberg Henry, Mcpherson Ruth

Centennial Collection: Pathogenesis of Atherothrombotic Events: From Lumen to Lesion and Beyond

Libby Peter

You have to be authorized to contact abstract author. Please, Login
Not Available